PRESS RELEASE published on 12/09/2025 at 13:04, 8 months 1 day ago Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada Formycon AG and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada. Agreement includes milestone payments, development progress, and upcoming data release Formycon AG Biosimilar Keytruda Zydus Exclusive Licensing
BRIEF published on 12/04/2025 at 06:35, 8 months 6 days ago Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
BRIEF published on 12/04/2025 at 06:35, 8 months 6 days ago Formycon et MS Pharma collaborent pour le biosimilaire de Keytruda® au Moyen-Orient et en Afrique du Nord MS Pharma Keytruda® FYB206 Accord Sur Les Biosimilaires Marché MENA Partenariat Formycon
PRESS RELEASE published on 12/04/2025 at 06:30, 8 months 6 days ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 8 months 16 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
BRIEF published on 11/24/2025 at 06:35, 8 months 16 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
PRESS RELEASE published on 11/24/2025 at 06:30, 8 months 16 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 8 months 20 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
BRIEF published on 11/20/2025 at 17:05, 8 months 20 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
PRESS RELEASE published on 11/20/2025 at 17:00, 8 months 20 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
Published on 08/10/2026 at 15:30, 3 hours 12 minutes ago Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 3 hours 17 minutes ago Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 4 hours 12 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 5 hours 12 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 13:00, 5 hours 42 minutes ago Alaska Energy Metals Announces Drilling Program for the Mcbride Prospect, Angliers-Belleterre Project, Quebec, Canada
Published on 08/10/2026 at 18:29, 12 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 52 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 17:38, 1 hour 4 minutes ago PATRIZIA delivers strong earnings growth with EUR 42.7m EBITDA (+46.6% y-o-y) in H1 2026
Published on 08/10/2026 at 17:11, 1 hour 31 minutes ago CORRECTION FROM SOURCE: North Peak Commences 2026 Drilling Campaign at Prospect Mountain, Eureka, Nevada
Published on 08/10/2026 at 16:12, 2 hours 29 minutes ago dK Calls on PANDION AG Bondholders to Join Forces
Published on 08/10/2026 at 18:00, 42 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 42 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 11:53, 6 hours 48 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
